A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Single Intravenous and Subcutaneous Doses of GZ402668 in Men and Women With Progressive Multiple Sclerosis

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs GZ 402668 (Primary) ; GZ 402668 (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; First in man
  • Sponsors Genzyme Corporation
  • Most Recent Events

    • 28 Oct 2017 Results of pharmacodynamic effects of intravenous and subcutaneous doses of GLD52 on innate and adaptive immune cells presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results (n=44) assessing safety, tolerability and pharmacodynamics of ascending single intravenous (IV) and subcutaneous (SC) doses of GLD52 in patients with progressive MS, were presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis.
    • 28 Apr 2017 Results (n=44) presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top